Entero Therapeutics Stock Jumps 62% Ahead of Phase 3 Latiglutenase Trial and $6M Raise

Introduction

Entero Therapeutics Inc. (Nasdaq: ENTO) is a late clinical-stage biopharmaceutical company headquartered in Boca Raton, Florida. Founded in 2014 as First Wave BioPharma, the company develops targeted, non-systemic therapies for gastrointestinal diseases, including celiac disease, gastroparesis, exocrine pancreatic insufficiency, and inflammatory bowel disorders.

Corporate Structure

Entero Therapeutics employs between 11 and 50 professionals across research, clinical operations, and regulatory affairs. The leadership team is headed by Chairman and Chief Executive Officer James Sapirstein, who oversaw the company’s rebranding on May 16, 2024. According to its amended S-1 filing dated July 2, 2025, Richard Paolone is identified as the Interim Chief Executive Officer during the public offering process. The board includes Dr. Ezio Syage, co-founder of ImmunogenX and an expert in mass spectrometry and trace chemical detection.

Gastrointestinal therapies by Ignacio Campo

Developments and News

On May 16, 2024, the company announced its name change from First Wave BioPharma to Entero Therapeutics, and its Nasdaq ticker switched to ENTO on May 17, 2024. The rebranding is aligned with preparations for a Phase 3 trial of latiglutenase, an oral biotherapeutic designed to reduce celiac disease symptoms. The U.S. Food and Drug Administration has reviewed the Phase 3 plan, with trial initiation expected in early 2025.
On November 13, 2024, Entero Therapeutics disclosed a proposed reverse merger with Journey Therapeutics, intending to combine its gastrointestinal pipeline with Journey’s nano-immunoconjugate oncology platform.
In its S-1/A amendment filed on July 2, 2025, the company registered an offering of 12,000,000 common shares and pre-funded warrants exercisable for 12,000,000 additional shares. The estimated public offering price is $0.50 per share, with a $0.0001 exercise price for each warrant. Subsequent Form 8-K filings on July 8 and July 16, 2025, detailed material corporate events under Items 8.01, 1.01, and 9.01.

Financial and Strategic Analysis

On August 11, 2025, Entero Therapeutics’ shares closed at $0.5928, reflecting a 62.46 percent increase on a volume of 15,323,170 shares traded on the Nasdaq Capital Market. This increase followed anticipation of the capital raise and the upcoming Phase 3 trial. The July 2, 2025 S-1/A filing targets gross proceeds of approximately $6 million to extend the cash runway and fund clinical operations. While the issuance of pre-funded warrants may dilute existing shareholders, it highlights the strategic priority of advancing late-stage assets. Regular 8-K disclosures underscore the company’s commitment to timely SEC reporting.

Market Position and Industry Context

Entero Therapeutics focuses on gastrointestinal disorders characterized by significant unmet medical needs and few approved treatments. Its pipeline comprises three proprietary platforms:

• Latiglutenase: a Phase 3 oral biotherapeutic for celiac disease, which currently has no approved drugs.
• Capeserod: a Phase 2 selective 5-HT4 receptor partial agonist for gastroparesis and other gastrointestinal indications.
• Adrulipase: a Phase 2 recombinant lipase enzyme for exocrine pancreatic insufficiency in cystic fibrosis and chronic pancreatitis.

The proposed merger with Journey Therapeutics could diversify Entero’s portfolio into oncology, aligning with an industry trend of integrating modular therapeutic platforms to address multiple disease areas.

tl;dr

On August 11, 2025, Entero Therapeutics saw its stock close at $0.5928, marking a 62.46 percent increase with 15.3 million shares traded, driven by the anticipation of the Phase 3 latiglutenase trial expected in early 2025 and a $6 million capital raise through a combined offering of common shares and pre-funded warrants. The company is also proceeding with a proposed merger with Journey Therapeutics to incorporate an oncology-focused nano-immunoconjugate platform.